Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Emerald Health Therapeutics Inc EMHTF

Healthcare Drug Manufacturers - Specialty & Generic Cannabis
Emerald is committed to creating new consumer experiences with distinct recreational, medical and wellness-oriented cannabis products with an emphasis on innovation and production excellence.


OTCQB:EMHTF - Post by User

Emerald Health Therapeutics Inc > Second-Quarter-Financial-Result 2021!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(41)
•••
Comment by Stockqueen77on Sep 02, 2021 3:52pm
147 Views
Post# 33804504

RE:RE:RE:Second-Quarter-Financial-Result 2021!

RE:RE:RE:Second-Quarter-Financial-Result 2021!
Hahaha.....everyone should go buy Punit's new book Catapult, seriously what a joke. If he's not stopped by securities he'll be just like his uncle or even worse.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities